A Noval Established Cuproptosis-Associated LncRNA Signature for Prognosis Prediction in Primary Hepatic Carcinoma

Figure 3

(a) Distribution of risk scores in the training cohort of patients with PHC, based on CRLRs. (b) Scatter plots show the association between the OS and the risk score in the training cohort of PHC patients, according to prognostic features of CRLRs. (c) A heat map shows seven CRLRs (MIR210HG, AC099850.3, AL031985.3, AC012073.1, MKLN1-AS, KDM4A-AS1, and PLBD1-AS1) with high expression in high-risk patients in the training cohort. (d) KM survival curve analysis of the training cohort. (e) Area under the ROC curve for the training cohort, based on CRLR-based prognostic features at 12 months. (f) Distribution of risk scores in the testing cohort of patients with PHC, based on CRLRs. (g) Scatter plots show the association between the OS and the risk score in the testing cohort of PHC patients, according to prognostic features of CRLRs. (h) A heat map shows the same seven CRLRs with high expression in high-risk patients in the testing cohort. (i) KM survival curve analysis of the testing cohort. (j) Area under the ROC curve for the testing cohort, based on CRLRs-based prognostic features at 12 months. (k) Distribution of risk scores for the entire cohort of patients with PHC, based on CRLRs. (l) Scatter plots show the association between the OS and the risk score for the entire cohort of PHC patients, according to prognostic features of CRLRs. (m) Heat map shows the same seven CRLRs with high expression in high-risk patients among the entire cohort. (n) KM survival curve analysis of the entire cohort. (o) Area under the ROC curve for the entire cohort, based on CRLRs-based prognostic features at 12 months.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)